Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation
(2 available);
any
Kras mutation
(76 available)
Tg(Cela1-tTA)#Eps mutation
(0 available)
Tg(tetO-cre)3Jig mutation
(0 available)
Trp53tm1Brd mutation
(5 available);
any
Trp53 mutation
(232 available)
|
|
|
mortality/aging
|
|
• 50% mortality by 6 months of age
• 100% mortality by 1 year of age
|
neoplasm
|
|
• all mice develop moderately to poorly differentiated pancreatic ductal adenocarcinomas, peritoneal explants, and perineural extensions
|
|
|
• metastases develop affecting liver, diaphragm, lungs, lymph nodes, and spleen
|
endocrine/exocrine glands
|
|
• all mice develop moderately to poorly differentiated pancreatic ductal adenocarcinomas, peritoneal explants, and perineural extensions
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Clcn3tm1.1Jrhm mutation
(0 available);
any
Clcn3 mutation
(119 available)
Tg(Myh6-tTA)6Smbf mutation
(4 available)
Tg(tetO-cre)3Jig mutation
(0 available)
|
|
|
mortality/aging
|
|
• adult mice maintained off doxycline beyond the 3 week time point show increased mortality relative to age-matched on doxycline control mice
|
cardiovascular system
|
|
• at 3 weeks off doxycline, adult mice exhibit dramatically enlarged hears relative to age-matched on doxycline control mice
|
|
|
• at 3 weeks off doxycline, adult mice display severe signs of myocardial hypertrophy
|
|
|
• at 3 weeks off doxycycline, adult mice show a significantly increased heart mass and heart mass:body weight ratio relative to age-matched on doxycline control mice
• however, body weight is not significantly altered at 3 weeks off doxycycline
|
|
|
• at 1.5 and 3 weeks off doxycycline, adult mice display dilated cardiomyopathy (DCM), unlike age-matched on doxycline control mice
• DCM is more pronounced at 3 weeks off doxycycline
|
|
|
• at 3 weeks off doxycline, adult mice show significantly reduced left ventricular ejection fraction (LVEF) and fractional shortening (%FS) relative to age-matched on doxycline control mice
|
|
|
• M-mode echocardiography revealed a significant increase in the chamber cavity (left ventricular internal diameter, systolic [LVIDs] and LVID, diastolic [LVIDd]), left ventricular mass (LVM) and LVM/body weight ratio, and a marked decrease in LVEF and %FS in mice off doxycycline for 1.5 and 3 weeks relative to age-matched on doxycline control mice
|
|
|
• electrophysiological analysis of native volume-sensitive chloride channels (VSOACs) in isolated atrial and ventricular myocytes 3 weeks off doxycycline revealed a complete elimination of hypotonic-induced VSOAC currents, whereas at 1.5 weeks, VSOAC current densities are significantly reduced, relative to age-matched on doxycycline controls; no difference in current densities are noted under isotonic conditions prior to cell swelling
• membrane capacitance is significantly increased in ventricular myocytes from mice 3 weeks off doxyclycline relative to ventricular myocytes from on doxycycline control mice; however, no difference in membrane capacitance is noted in atrial myocytes at 3 weeks off doxycycline
• at 1.5 weeks off doxycycline, residual hypotonic-induced VSOAC currents are totally abolished in isolated atrial myocytes by perfusion of 100 nM PDBu (a protein kinase C activator), similar to VSOAC currents in atrial cells from on doxycycline control mice
|
|
|
• at 3 weeks off doxycline, adult mice display severe signs of heart failure
|
muscle
|
|
• at 3 weeks off doxycline, adult mice display severe signs of myocardial hypertrophy
|
|
|
• at 1.5 and 3 weeks off doxycycline, adult mice display dilated cardiomyopathy (DCM), unlike age-matched on doxycline control mice
• DCM is more pronounced at 3 weeks off doxycycline
|
|
|
• at 3 weeks off doxycline, adult mice show significantly reduced left ventricular ejection fraction (LVEF) and fractional shortening (%FS) relative to age-matched on doxycline control mice
|
growth/size/body
|
|
• at 3 weeks off doxycline, adult mice exhibit dramatically enlarged hears relative to age-matched on doxycline control mice
|
|
|
• at 3 weeks off doxycline, adult mice display severe signs of myocardial hypertrophy
|
|
|
• at 3 weeks off doxycycline, adult mice show a significantly increased heart mass and heart mass:body weight ratio relative to age-matched on doxycline control mice
• however, body weight is not significantly altered at 3 weeks off doxycycline
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation
(2 available);
any
Kras mutation
(76 available)
Tg(Cela1-tTA)#Eps mutation
(0 available)
Tg(tetO-cre)3Jig mutation
(0 available)
|
|
|
neoplasm
|
|
• focal morphological lesions develop in acinar and centroacinar cells at 1-3 months
• acinar to ductal metaplasias develop
• some mice develop ductal adenocarcinomas by 12 months
• properties are similar to those in human patients
• sometimes areas of non malignant hyperplasia develop
|
|
|
• latency is increased if gene expression is delayed by maintaining exposure to doxycycline until 10 days of age
• if doxycycline exposure continues to 2 months of age, no pancreatic abnormalities develop
|
endocrine/exocrine glands
|
|
• focal morphological lesions develop in acinar and centroacinar cells at 1-3 months
• acinar to ductal metaplasias develop
• some mice develop ductal adenocarcinomas by 12 months
• properties are similar to those in human patients
• sometimes areas of non malignant hyperplasia develop
|
Analysis Tools